Metalgial is indicated for the management of moderate to severe pain. Its authorized therapeutic domains focus on addressing pain that is not adequately relieved by other available treatment options.

Metalgial has been used in a clinical context for the relief of various types of acute discomfort, including pain experienced following surgical procedures or injuries, as well as pain associated with colic or tumors.

The medication also has a recognized utility in the reduction of high fever, particularly when the elevated temperature has not responded to other established fever-reducing interventions.

---

Quick Facts: Therapeutic Overview

• Relief of moderate to severe pain.
• Reduction of high fever that is refractory to other interventions.
• Management of acute postoperative, post-traumatic, colic, or tumor-related pain.

---

Metalgial is a medicine containing metamizole, which is authorized for use in several countries for these established therapeutic indications. Patients are advised to consult their healthcare provider for an individualized assessment of its potential benefits and risks.

Regulatory References

1. EMA therapeutic overview of metamizole

Who can and cannot use Metalgial?

Eligibility for Metalgial (Sodium Metamizole) is strictly defined by regulatory documents, which establish specific restrictions and contraindications based on age, pre-existing conditions, and physiological status.

Population Eligibility Status	Official Regulatory Stance
Eligible Populations	Adults and adolescents 15 years and older. Children are eligible from 3 months of age (or minimum 5 kg body weight) with appropriate formulations.
Contraindicated Populations	Infants under 3 months or 5 kg. Patients with a history of known hypersensitivity or agranulocytosis to metamizole or other pyrazolones.
Absolute Contraindications	History of impaired bone marrow function; diseases of the haematopoietic system; acute intermittent hepatic porphyria; or genetic G6PD deficiency.
Pregnancy/Lactation	Contraindicated in the third trimester of pregnancy. Not recommended in the first two trimesters. During lactation, breast milk must be discarded for 48 hours following a single dose.

Restricted and Conditional Use:

Use requires caution in the elderly and in patients with severe renal or hepatic impairment, particularly for prolonged or high-dose administration, where multiple high doses must be avoided. Caution is also advised in patients with circulatory instability or pre-existing hypotension.

Metalgial Interactions with Other Medicines and Products

The interaction profile for Metalgial (Sodium Metamizole) is primarily defined by its effects on drug metabolism and function as described in official regulatory documents.

Pharmacokinetic and Pharmacodynamic Interactions

Metalgial is documented as a moderate to strong inducer of multiple Cytochrome P450 enzymes, including CYP3A4, CYP2B6, and CYP2C19, and a weak inducer of CYP2C9. Additionally, it is a moderate inhibitor of CYP1A2.

This enzyme activity results in the reduced plasma concentration of co-administered medicines like Cyclosporine, Midazolam, Bupropion, Methadone, and Quetiapine, which may reduce their therapeutic effect. Metalgial may also decrease the excretion rate of certain agents, such as Abacavir and Acetaminophen, potentially elevating their serum levels.

A significant pharmacodynamic interaction exists with low-dose Acetylsalicylic acid (ASA), where Metalgial inhibits its anti-platelet effect when taken at the same time. Co-administration with other myelosuppressive drugs can increase the risk of specific adverse effects.

Administration Constraints

To mitigate the functional interference with low-dose ASA used for cardioprotection, official regulatory documents stipulate a timing-based rule: Metalgial must be administered at least 30 minutes after or several hours before the ASA dose. No combinations are formally categorized as contraindicated in the context of drug-drug co-administration.

Modulation of Inflammatory and Nociceptive Signaling Cascades

Metalgial modulates signaling through dual peripheral mechanisms. First, it acts on humoral pathways by non-selectively inhibiting COX-1 and COX-2 enzymes, which suppresses the synthesis of prostaglandins that function as pyrogens and algogens. Second, it interferes with neuronal electrical signaling by non-competitively blocking Voltage-Gated Sodium Channels ( VGSCs) in nerve endings, thereby inhibiting the generation and propagation of the afferent neural action potential. This results in reduced prostaglandin-mediated responses and blocked action potential conduction.

Regulation of Central Inhibitory Pathways

The drug engages a third domain by acting within the central nervous system ( CNS) to regulate motor processes. Specifically, Metalgial functions as a Positive Allosteric Modulator ( PAM) of the inhibitory GABAA receptor, enhancing the effects of the endogenous inhibitory neurotransmitter, GABA. This results in a reduction of neuronal excitability and supports a regulated state within the motor pathways, leading to a physiological adjustment of reduced motor neuron excitability.

Administration Instructions for Metalgial

The use of Metalgial (metamizole) must adhere strictly to established dosing and procedural guidelines. Treatment should consistently begin at the lowest recommended dose that controls the symptoms, and doses should only be increased if necessary.

---

Dosing and Route

Metalgial is administered orally (by mouth) and via injection (intramuscular or intravenous), with suppositories also available. The dosage schedule is dependent on age and body weight.

Age Group	Single Oral Dose	Maximum Daily Oral Dose	Procedural Note
Adults & Adolescents (≥ 15 years or > 53 kg)	Up to 1,000 mg	4,000 mg (up to 4 times daily)	Minimum 6-8 hour interval between doses.
Children (up to 14 years)	8-16 mg per kg body weight	Dose is strictly weight-based.	Consult specific product forms for accurate dosing.

Procedural Requirements

• Intravenous Injection: If administering by the intravenous route, the injection must be given very slowly to mitigate the risk of a severe hypotensive reaction. The total daily dose for all injection routes must not exceed 5,000 mg.
• Infants: For children under 1 year of age, the medication should only be administered by the intramuscular route.
• Missed Dose: In the event of a missed dose, consult your prescriber. The frequency pattern for oral use is daily, limited to a maximum of four administrations per 24-hour period.

---

This structured protocol establishes the guidelines for administration, defining the allowable routes, the specific, weight-based rules for pediatric patients, and the maximum limits for daily and single-dose consumption.

Research Evidence / Overview of Studies

Core Efficacy Research: Acute Pain Management

A substantial volume of research, including multiple randomized controlled trials (RCTs) and systematic reviews, has explored whether the drug was linked to changes in reported severe, acute pain and measures of inflammation.

The research findings relate to studies conducted in various settings, including immediate post-operative or injury-related pain.

---

Long-Term Outcomes: Chronic Pain and Quality of Life

Beyond acute settings, several observational cohort studies and a few long-term follow-up RCTs have evaluated whether the drug showed an association with changes in quality of life measures for individuals with chronic pain.

• Observed Effects: These studies primarily focused on outcomes such as mobility, sleep patterns, and the ability to perform daily activities over periods ranging from six months to two years.
• Pain Intensity: Research findings included reports of a change in pain intensity over the study periods.

---

Adverse Effect Reporting Profile

Research included an examination of the drug’s reported adverse effects in comparison to placebo in trials across different patient populations.

• Adverse Events: In short-term studies, the incidence of common adverse events (e.g., gastrointestinal upset, mild dizziness) was reported to be similar between the active treatment group and the placebo group.
• Long-Term Assessment: Studies included an assessment of the drug’s use over longer periods. The primary focus of these assessments was on potential effects on major organ systems.
• Additional Findings: Another finding was an evaluation of the drug’s profile of adverse effects.

Common questions about Metalgial (FAQ)

Q: How quickly does Metalgial usually start to work?

Regulatory data, specifically the drug's pharmacokinetic profile, describes key characteristics of how the medicine works in the body. According to this information, the main active component reaches its peak concentration in the blood, known as Tmax, typically between 1.4 and 2.0 hours after a dose is taken by mouth.

Q: How long does the effect of Metalgial typically last?

Official information defines the half-life of the drug's active metabolite, which is a measure of how long it takes for the concentration in the body to be reduced by half. The half-life for this active substance is reported to range from 2.6 to 3.5 hours.

Q: Is it common to feel tired after taking Metalgial?

The official safety profile for Metalgial includes potential side effects like dizziness. Additionally, official information indicates that the medication may impair your ability to be alert or focused.

Q: Will Metalgial cause problems if I have a sensitive stomach?

Safety information reports that gastrointestinal issues have been observed in some people using the drug. These events include common issues such as nausea, vomiting, abdominal pain, and indigestion (dyspepsia).

Q: Is it true that Metalgial can interact with blood thinners?

Yes, official documents describe a specific interaction between Metalgial and low-dose Acetylsalicylic acid (ASA), which is a common type of blood thinner used for cardioprotection. Regulatory information indicates that Metalgial can inhibit the anti-platelet effect of ASA when they are taken at the same time.

Q: Does alcohol interact negatively with Metalgial?

The official patient information often includes a statement that it is not known whether consuming alcohol affects the way Metalgial works. For specific direction, official guidance defers questions about using alcohol while taking the medicine to a healthcare provider.

Q: What is the difference between a contraindication and a warning for Metalgial?

In regulatory documents, a contraindication identifies a condition or patient group for whom the medicine must never be used, such as during the third trimester of pregnancy. A warning or caution signifies a condition where use is restricted or requires special medical supervision, such as in patients with severe kidney impairment.

Q: Are there different strengths or versions of Metalgial available?

Regulatory product data indicates that Metalgial is supplied in different pharmaceutical forms. These include standard tablets for oral administration and a sterile solution for injection, which is used for parenteral (non-oral) use.

Q: Can Metalgial be used by older adults (e.g., over 65)?

Official guidance stipulates that the body's elimination of the drug's metabolites may be prolonged in elderly people. Due to this factor, a reduced dosage is generally described in official guidance for this population.

Q: What is the research evidence for Metalgial's long-term use?

Regulatory guidance on Metalgial indicates that its use should typically be limited to short-term treatments, such as a maximum duration of seven days. Official documents describe that for use beyond this period, hematological monitoring is a factor to consider.

Q: What should be done if a dose of Metalgial is missed?

Official governmental drug documents do not typically contain explicit, public-facing instructions for how to handle a single missed dose of Metalgial. Specific direction regarding missed doses is deferred to a medical professional.

Q: Can Metalgial cause dizziness or affect driving?

Official safety information includes dizziness as a potential side effect. Regulatory documents indicate that the drug may impair the ability to drive or operate machinery.

Q: Is Metalgial suitable for someone who has high blood pressure?

Caution is advised for patients with circulatory instability. The safety profile also lists hypotension (low blood pressure) as an uncommon adverse reaction. This information is provided in the official warnings.

Q: Is it OK to take Metalgial every day for a long period of time?

Regulatory bodies describe that use should generally be limited to short-term periods. Official guidance typically restricts use to a maximum of seven days, unless specific medical supervision is in place, such as hematological (blood) monitoring.

Q: What is the main way Metalgial leaves the body?

Official pharmacokinetic data states that the drug is processed into metabolites, and approximately 60% of these metabolites are excreted primarily via the urine.

Q: What is the maximum amount of time Metalgial is typically used for?

Regulatory bodies generally advise that Metalgial be used for short periods only. Official guidelines describe this short-term period as a maximum of seven days, unless specific medical monitoring is a factor.

Q: Why are there different instructions for how often to take Metalgial?

The required interval between doses is linked to the drug's pharmacokinetic profile. Dosing frequency is structured to ensure a minimum time passes between administrations—such as the required 6–8 hour interval—to manage the concentration of the medicine in the body.

Official Storage and Disposal Instructions

Metalgial's stability is maintained through specific regulatory storage conditions. The oral drops solution must be stored below 30°C, while the solution for injection must be stored not above 25°C and explicitly must not be frozen. The injectable form must be kept in its original package to protect from light.

For the oral drops, the bottle must be closed well after each use, and the solution's in-use shelf-life is 28 days after the first opening. All forms of Metalgial must be kept out of the sight and reach of children.

Disposal must follow strict pharmaceutical waste guidelines. The medicine must not be disposed of via wastewater or household waste and should be returned or discarded according to the local requirements for pharmaceuticals.